Comparative Pharmacology
Head-to-head clinical analysis: DECADRON LA versus HYDROCORTISONE IN ABSORBASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON LA versus HYDROCORTISONE IN ABSORBASE.
DECADRON-LA vs HYDROCORTISONE IN ABSORBASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
Topical: Apply a thin layer to affected area 2-4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site.
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%).
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Category C
Category D/X
Corticosteroid
Corticosteroid